Qiagen (QGEN) has released an update.
Qiagen N.V. reported a steady second quarter in 2024 with net sales of $496 million, a 1% increase at constant exchange rates (CER) over the previous year, and exceeded its earnings outlook with an adjusted EPS of $0.55. The company also saw a significant 56% rise in free cash flow to $129 million and increased its full-year outlook, expecting at least $1.985 billion in net sales and an adjusted EPS of at least $2.16. This financial uptick is attributed to strong core business performance and strategic product focus, despite phasing out the NeuMoDx system.
For further insights into QGEN stock, check out TipRanks’ Stock Analysis page.
